Roles of circRNAs in cancer chemoresistance (Review)
- Authors:
- Chuan Xin
- Fei Huang
- Jiongke Wang
- Jing Li
- Qianming Chen
-
Affiliations: State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, P.R. China - Published online on: September 1, 2021 https://doi.org/10.3892/or.2021.8176
- Article Number: 225
This article is mentioned in:
Abstract
 |
 |
 |
|
Bach DH, Lee SK and Sood AK: Circular RNAs in cancer. Mol Ther Nucleic Acids. 16:118–129. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sanger HL, Klotz G, Riesner D, Gross HJ and Kleinschmidt AK: Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci USA. 73:3852–3856. 1976. View Article : Google Scholar : PubMed/NCBI | |
|
Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW and Vogelstein B: Scrambled exons. Cell. 64:607–613. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Barrett SP and Salzman J: Circular RNAs: Analysis, expression and potential functions. Development. 143:1838–1847. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu N, Chen S, Liu Y, Li W, Liu Z, Bian X, Ling C and Jiang M: Profiles and bioinformatics analysis of differentially expressed circrnas in taxol-resistant non-small cell lung cancer cells. Cell Physiol Biochem. 48:2046–2060. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou R, Chen KK, Zhang J, Xiao B, Huang Z, Ju C, Sun J, Zhang F, Lv XB and Huang G: The decade of exosomal long RNA species: An emerging cancer antagonist. Mol Cancer. 17:752018. View Article : Google Scholar : PubMed/NCBI | |
|
Solassol I, Pinguet F and Quantin X: FDA- and EMA-Approved tyrosine kinase inhibitors in advanced EGFR-Mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 9:6682019. View Article : Google Scholar : PubMed/NCBI | |
|
Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lei K, Bai H, Wei Z, Xie C, Wang J, Li J and Chen Q: The mechanism and function of circular RNAs in human diseases. Exp Cell Res. 368:147–158. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med. 16:2202018. View Article : Google Scholar : PubMed/NCBI | |
|
Bayani J, Kuzmanov U, Saraon P, Fung WA, Soosaipillai A, Squire JA and Diamandis EP: Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: Impact on kallikrein 6 protein expression. Clin Chem. 59:296–305. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses cell apoptosis via inhibition of miR196a5p by targeting BIRC3 in OSCC. Oncol Rep. 39:951–966. 2018.PubMed/NCBI | |
|
Li X, Yang L and Chen LL: The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 71:428–442. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo JU, Agarwal V, Guo H and Bartel DP: Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 15:4092014. View Article : Google Scholar : PubMed/NCBI | |
|
Kristensen LS, Hansen TB, Venø MT and Kjems J: Circular RNAs in cancer: Opportunities and challenges in the field. Oncogene. 37:555–565. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P and Yang BB: Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 44:2846–2858. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Conn VM, Hugouvieux V, Nayak A, Conos SA, Capovilla G, Cildir G, Jourdain A, Tergaonkar V, Schmid M, Zubieta C and Conn SJ: A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants. 3:170532017. View Article : Google Scholar : PubMed/NCBI | |
|
Dong R, Zhang XO, Zhang Y, Ma XK, Chen LL and Yang L: CircRNA-derived pseudogenes. Cell Res. 26:747–750. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L and Chen LL: Circular intronic long noncoding RNAs. Mol Cell. 51:792–806. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, Kim J, Noh JH, Kim KM, Martindale JL and Gorospe M: Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 14:361–369. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, et al: Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 7:124292016. View Article : Google Scholar : PubMed/NCBI | |
|
Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, Hanan M, Wyler E, Perez-Hernandez D, Ramberger E, et al: Translation of CircRNAs. Mol Cell. 66:9–21.e7. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tang C, Xie Y, Yu T, Liu N, Wang Z, Woolsey RJ, Tang Y, Zhang X, Qin W, Zhang Y, et al: m6A-dependent biogenesis of circular RNAs in male germ cells. Cell Res. 30:211–228. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, et al: Circ-ZNF609 Is a Circular RNA that can be translated and functions in myogenesis. Mol Cell. 66:22–37.e9. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas H and Coley HM: Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Shapira A, Livney YD, Broxterman HJ and Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Updat. 14:150–163. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI | |
|
Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hashida S, Soh J, Toyooka S, Furukawa M, Shien K, Yamamoto H, Asano H, Tsukuda K, Hagiwara K and Miyoshi S: Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncol Rep. 32:145–152. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zakharenko A, Dyrkheeva N and Lavrik O: Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity. Med Res Rev. 39:1427–1441. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B and Köberle B: Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer. 9:2482010. View Article : Google Scholar : PubMed/NCBI | |
|
Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW and O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:5824–5830. 1994.PubMed/NCBI | |
|
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
White E, Mehnert JM and Chan CS: Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
White E and DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI | |
|
Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, et al: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 28:1713–1729. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hoyt K, Castaneda B, Zhang M, Nigwekar P, di Sant'agnese PA, Joseph JV, Strang J, Rubens DJ and Parker KJ: Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomark. 4:213–225. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W and Howell SB: Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 4:1595–1604. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Chen G, Sun D, Lei M, Li Y, Zhou C, Li X, Xue W, Wang H, Liu C and Xu J: Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai). 49:808–816. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al: Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 343:72–76. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu HH, Kuo WW, Shih HN, Cheng SF, Yang CK, Chen MC, Tu CC, Viswanadha VP, Liao PH and Huang CY: FOXC1 regulation of miR-31-5p confers oxaliplatin resistance by targeting LATS2 in colorectal cancer. Cancers (Basel). 11:15762019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Chen X, Xu M, Liu X, Pan B, Qin J, Xu T, Zeng K, Pan Y, He B, et al: miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. Aging (Albany NY). 11:7357–7385. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, Xu Z, Zeng A, Zhang X, Zhang X, et al: Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 18:712019. View Article : Google Scholar : PubMed/NCBI | |
|
Yan L, Liu G, Cao H, Zhang H and Shao F: Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 519:172–178. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lapa RML, Barros-Filho MC, Marchi FA, Domingues MAC, de Carvalho GB, Drigo SA, Kowalski LP and Rogatto SR: Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients. Oral Oncol. 93:76–84. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Bao C, Zhao F, Yu H, Zhong G, Xu L and Yan S: Exploring specific miRNA-mRNA axes with relationship to taxanes-resistance in breast cancer. Front Oncol. 10:13972020. View Article : Google Scholar : PubMed/NCBI | |
|
Kong F, He S, Shen X, Li L, Fang J and Lian M: Integrated analysis of different mRNA and miRNA profiles in human hypopharyngeal squamous cell carcinoma sensitive and resistant to chemotherapy. Neoplasma. 67:473–483. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, Lo-Coco F, Tay Y, Beck AH and Pandolfi PP: Oncogenic role of Fusion-circRNAs Derived from cancer-associated chromosomal translocations. Cell. 165:289–302. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dos Santos GA, Kats L and Pandolfi PP: Synergy against PML-RARa: Targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 210:2793–2802. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Y, Lou J, Wang H, An N, Chen H, Zhang Q and Du X: CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis. 73:38–44. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Q, Huo N, Wang X, Yang S, Wang J and Zhang T: Exosomes from oral tissue stem cells: Biological effects and applications. Cell Biosci. 10:1082020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Ji M, Wang Q, He N and Li Y: Circular RNA Cdr1as Upregulates SCAI to suppress cisplatin resistance in ovarian cancer via miR-1270 suppression. Mol Ther Nucleic Acids. 18:24–33. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Y and Gui R: Circulating Exosomal circMYC is associated with the recurrence and bortezomib resistance in patients with multiple myeloma. Turk J Haematol. 37:248–262. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z, Zhang G, Gu J and Kang D: Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 479:1–12. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S and Xia B: Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife. 6:e213502017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Fraser M, Abedini MR, Bai T and Tsang BK: Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shang J, Chen WM, Liu S, Wang ZH, Wei TN, Chen ZZ and Wu WB: CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res. 85:1061982019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Dong Y, Zhao L, Su L and Luo J: Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 53:1752–1762. 2018.PubMed/NCBI | |
|
Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther. 9:6421–6431. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang B, Yan LJ and Wu Q: ABCB1 (C1236T) polymorphism affects P-glycoprotein-mediated transport of methotrexate, doxorubicin, actinomycin D, and etoposide. DNA Cell Biol. 38:485–490. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang MS, Yuan FQ, Gao Y, Liu JY, Chen YX, Wang CJ, He BM, Zhou HH and Liu ZQ: Circular RNA screening from EIF3a in lung cancer. Cancer Med. 8:4159–4168. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Su Y, Yang W, Jiang N, Shi J, Chen L, Zhong G, Bi J, Dong W, Wang Q, Wang C and Lin T: Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance. Int J Biol Sci. 15:441–452. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ping L, Jian-Jun C, Chu-Shu L, Guang-Hua L and Ming Z: High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance. Oncol Res. Feb 14–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Joseph NA, Chiou SH, Lung Z, Yang CL, Lin TY, Chang HW, Sun HS, Gupta SK, Yen L, Wang SD and Chow KC: The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. J Hematol Oncol. 11:742018. View Article : Google Scholar : PubMed/NCBI | |
|
Kotmakçı M, Çetintaş VB and Kantarcı AG: Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells. Int J Pharm. 525:101–111. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Garofalo M and Croce CM: MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 16:47–59. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, Zhang N, Zhang H, Liu Y, Chen T, et al: circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther. 27:1638–1652. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Reshke R, Taylor JA, Savard A, Guo H, Rhym LH, Kowalski PS, Trung MT, Campbell C, Little W, Anderson DG and Gibbings D: Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat Biomed Eng. 4:52–68. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liang Y, Song X, Li Y, Su P, Han D, Ma T, Guo R, Chen B, Zhao W, Sang Y, et al: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 38:6850–6866. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Gu J, Wang X, Wang Y, Feng M, Zhou D, Guo J and Zhou M: Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7. J Cell Mol Med. 23:3166–3177. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu W, Peng W, Sha H and Li J: Hsa_circ_0003998 promotes chemoresistance via modulation of miR-326 in lung adenocarcinoma cells. Oncol Res. 27:623–628. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shang J, Chen WM, Wang ZH, Wei TN, Chen ZZ and Wu WB: CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol. 70:42–54.e3. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kun-Peng Z, Xiao-Long M, Lei Z, Chun-Lin Z, Jian-Ping H and Tai-Cheng Z: Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics. 10:1327–1346. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Zhang J, Qin L, Yang Z, Xiong J, Zhang Y, Li R, Li S, Wang H, Yu B, et al: Circular RNA EIF6 (hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. Aging (Albany NY). 10:3806–3820. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao D, Qi X, Zhang X, Fang K, Guo Z and Li L: hsa_circRNA_0006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-7-5p and activating the MAPK/ERK signaling pathway. Mol Carcinog. 58:554–564. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Zheng X, Xu B, Chen L, Wang Q, Deng H and Jiang J: Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys Res Commun. 508:527–535. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hua X, Sun Y, Chen J, Wu Y, Sha J, Han S and Zhu X: Circular RNAs in drug resistant tumors. Biomed Pharmacother. 118:1092332019. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong W, Ai YQ and Li YF, Ye Q, Chen ZT, Qin JY, Liu QY, Wang H, Ju YH, Li WH and Li YF: Microarray analysis of circular RNA expression profile associated with 5-fluorouracil-based chemoradiation resistance in colorectal cancer cells. Biomed Res Int. 2017:84216142017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T and Zhang L: Analyzing the interactions of mRNAs and ncRNAs to predict competing endogenous RNA Networks in osteosarcoma Chemo-Resistance. Mol Ther. 27:518–530. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chi BJ, Zhao DM, Liu L, Yin XZ, Wang FF, Bi S, Gui SL, Zhou SB, Qin WB, Wu DM and Wang SQ: Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance. Neoplasma. 66:197–202. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao G, Niu Y, Wu D and Chang C: Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. Cell Death Dis. 10:372019. View Article : Google Scholar : PubMed/NCBI |
